Expert Interviews

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

Panelists discuss how real-world patient cases demonstrate the importance of individualizing obstructive sleep apnea treatment plans by considering factors such as disease severity, comorbidities, lifestyle, and patient preferences to optimize outcomes.

Panelists discuss how treatment options for obstructive sleep apnea include positive airway pressure therapy, oral appliances, lifestyle modifications, and surgical interventions, with the choice depending on disease severity and patient preferences.

Panelists discuss how positive airway pressure therapy is the most effective treatment for obstructive sleep apnea, with optimal outcomes dependent on proper device settings, mask fitting, and patient education to improve adherence.

Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.

Panelists discuss how patient selection for teplizumab therapy requires screening for specific autoantibodies and stages of Type 1 diabetes, followed by a standardized 14-day outpatient infusion protocol with careful monitoring for side effects.

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.

Panelists discuss how islet autoantibody testing serves as a critical screening tool for identifying Type 1 diabetes risk, with tests detecting antibodies against insulin, GAD65, IA-2, and ZnT8 proteins being the most clinically validated markers.